Product Description: Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.
Applications: Cancer-Kinase/protease
Formula: C20H22ClF3N8O3S
Citations: Bioact Mater. 1 July 2021./Bioact Mater. 2021 Jun 1./bioRxiv. 2023 Mar 2./Mater Sci Eng C Mater Biol Appl. 2020 Jan;106:110221./Mol Metab. 2023 Feb 24;101698./Research Square Preprint. 2020 Jun./Research Square Preprint. 2021 Aug./ACS Appl Mater Interfaces. 2024 Oct 1./ACS Nano. 2023 Jan 4./Biochem Biophys Res Commun.. 2024 Sep 17./bioRxiv. 2024 November 26./Bone. 2021 Oct 12;116231./Cancer Commun (Lond). 2024 Jul 28./Cell Death Dis. 2021 Sep 23;12(10):868./Cell Mol Gastroenterol Hepatol. 2021;11(3):683-696./Clin Breast Cancer. 2024 Jan 26./Exp Cell Res. 12 October 2021, 112868./Exp Ther Med. 2020 Aug;20(2):1405-1414./Front Oncol. 2022 Apr 28;12:851065./Heliyon.2024 Aug 6;10(16):e35727./J Exp Clin Cancer Res. 2018 Jul 28;37(1):175./J Exp Clin Cancer Res. 2022 Sep 16;41(1):275./J Int Med Res. 2018 Apr;46(4):1311-1325. /J Orthop Transl. 2020 May 19;24:12-22./J Transl Med. 2023 Sep 19;21(1):640./Mol Carcinog. 2023 Oct 3./Nat Commun. 2023 Apr 29;14(1):2478./Nat Commun. 2019 Aug 16;10(1):3708. /Oncogene. 2023 Feb 23./Oncogene. 2024 Aug 22./Oncol Res. 2024 Mar 20;32(4):679-690./Phytomedicine. 21 July 2022, 154349./Placenta. 2024 Aug 21:156:30-37./Research Square Print. September 13th, 2022./Sci Data. 2024 Sep 19./Sci Rep. 2019 May 20;9(1):7617./Science. 2017 Dec 1;358(6367):eaan4368./University of Zürich. Department of Dermatology. 2021 Dec.
References: [1]Kang Y, et al. Role of focal adhesion kinase in regulating YB-1-mediated resistance in ovarian cancer. J Natl Cancer Inst. 2013 Oct 2;105(19):1485-95.
CAS Number: 1073160-26-5
Molecular Weight: 546.95
Compound Purity: 98.95
Research Area: Cancer
Solubility: DMSO : 6.67 mg/mL (ultrasonic)/H2O : < 0.1 mg/mL
Target: FAK
English
Deutsch
